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ABSTRACT
Background: Despite reported increases in referral numbers, a large proportion of those with pre-
diabetes still decline participation in the NHS England Diabetes Prevention Programme (NDPP). The aim 
of this study was to explore whether investment in interventions to improve uptake of the programme 
has the potential to be cost-effective.
Methods: An early cost-utility analysis was conducted using a Markov model parameterized based on 
secondary data sources. We explored different uptake scenarios and the impact that this had on the 
maximum allowable intervention price based on cost-effectiveness at the UK NICE willingness to pay 
threshold of £20,000 (US$ 25,913). Value of information analyses were conducted to explore the 
potential value of further research to resolve uncertainty at each uptake level.
Results: As uptake levels increase, the maximum allowable intervention price and overall expected 
value of removing decision uncertainty increases. For 5 percentage and 50 percentage points increase 
in uptake levels, the maximum allowable intervention price is £41.86 (US$ 54.23) and £418.59 (US$ 
542.34) per person, and the overall expected value of removing decision uncertainty are £361,818,839 
(US$ 468,786,625) and £1,468,712,316 (US$ 1,902,921,063) respectively.
Conclusion: There is headroom for investment in interventions that improve uptake to the NDPP, 
thereby allowing the programme itself to be delivered in a manner that remains cost-effective.
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1. Introduction
Diabetes mellitus (DM) is a global health priority [1], with 
415 million known cases worldwide, of which 91% are Type 
2 (T2DM) [2]. The global prevalence of T2DM is anticipated to 
rise to 637 million by 2045 [3]. In England, there are currently 
3.4 million people with T2DM, which is estimated to cost the 
NHS £8.8 billion (US$ 11.4 billion) a year [4]. The cost of 
treating T2DM therefore has a significant toll on health bud-
gets, with approximately 80% of the cost spent on treatment 
of associated complications such as stroke, kidney failure, 
neuropathy, and retinopathy [5].
Type 2 diabetes is preceded by a phase of impaired glucose 
regulation, described as prediabetes [6,7]. This is defined as 
a fasting plasma glucose (FPG) level of 5.5–6.9 mmol/l or 
HbA1c of 42–47 mmol/mol [8]. A substantial number (up to 
10%) of individuals with prediabetes progress to T2DM 
each year [9]. In the UK, individuals with prediabetes are 
identified through general practice (GP) patient registers and 
NHS Health Checks which are offered every 5 years for 40–74- 
year-olds [10]. Although several risk factors for prediabetes 
have been identified (including genetic factors, ethnicity and 
age), a large proportion of cases in the UK are associated with  
modifiable risk factors such as obesity [11]. Addressing these 
factors implies that the burden of complications is likely to be 
reduced (limiting the corresponding impact of such complica-
tions on the person’s quality of life) with the potential result of 
reduced economic consequences on NHS resources [2].
The NHS England Diabetes Prevention Programme (NDPP) 
has been commissioned in England to prevent or delay the 
onset of T2DM in adults identified as having prediabetes [12]. 
The NDPP was informed by proven Diabetes Prevention 
Programme models such as the United States Diabetes 
Prevention Programme (US DPP) [13,14] and the Finnish 
Diabetes Prevention Programme [15,16]. The NDPP is 
a behavioral change intervention, consisting of face-to-face 
sessions taking place over a minimum period of 9 months, 
aimed at supporting participants in making lifestyle changes 
to reduce their risk of developing T2DM [11]. Patients who 
have been diagnosed to be at risk by an HbA1c blood glucose 
test are referred to the NDPP by their GP. It is then the 
patient’s choice whether they take up the service. Despite 
reports that referrals have increased since its implementation, 
recent studies have reported low uptake and participation 
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[17–19]; thus, national targets remain unmet as a large pro-
portion of those identified as having prediabetes decline to 
participate [20]. Sex, age, socioeconomic status, mode of refer-
ral, risk communication at referral and the perceived impact of 
the NDPP have been highlighted as factors that affect uptake 
[17–19]. Uptake is slightly higher among women than men, 
decreases with older age, lowest among those living in the 
most deprived areas and much higher among referrals via 
letters compared with consultation [17–19]. Better risk com-
munication, motivating patients, and the need for specific, 
more resource-intensive ‘warm’ recruitment approaches to 
capture the ‘right’ patients have been proposed as strategies 
that could benefit uptake and participation in the programme 
[18,19]. Considering the observed current trend, an increase in 
coverage through interventions that can potentially improve 
uptake to the programme is therefore likely to become 
a priority for the NHS because, the public health impact of 
a Diabetes Prevention Programme depends on participation 
as well as population coverage [21]. Interventions that 
improve uptake to the NDPP may have potential economic 
value in themselves. Despite a lot of work done to evaluate 
the cost-effectiveness of interventions that improve uptake to 
other public health programmes [22–26], the cost- 
effectiveness of interventions to increase uptake to the NDPP 
has not been explored. To the best of our knowledge, there is 
one study that has assessed the potential return on invest-
ment of the NDPP itself [27] and a recent study that has 
examined the likely cost-effectiveness of a hypothetical inter-
vention to delay progression to T2DM [28] but not the poten-
tial cost-effectiveness of an intervention that increases uptake 
to the NDPP.
The aim of this study was to determine, via an early eco-
nomic evaluation [29], the cost-effectiveness of an 
intervention to improve uptake of NDPP and to estimate the 
maximum allowable intervention price based on cost- 
effectiveness [30]. The intervention could, for example, take 
the form of a biomarker-based test, could be a risk score or 
could take the form of incentives by providing shopping 
vouchers for individuals that complete the programme.
2. Methods
A cost-utility analysis was conducted (using a Markov model 
developed in Microsoft Excel 2016) to examine the potential 
cost-effectiveness of an intervention to improve uptake of 
NDPP. The patient population considered consists of indivi-
duals identified as pre-diabetic through GP patient registers 
and NHS Health Checks in primary care and eligible for the 
NDPP but having previously declined to participate. This 
subpopulation – rather than everyone identified as having 
prediabetes – was considered in this analysis, because 
about 56% of the total pre-diabetic population will take 
up NDPP when offered to them [31]. This means that giving 
an additional intervention to everyone would be unneces-
sary for those who would have taken up NDPP anyway and 
highlights the need to target the right patients (i.e. those 
who have previously declined to participate). It is worth 
highlighting that although these patients are being referred 
to as ‘decliners’, not all of them may have actually declined 
but could have either missed their initial NDPP appointment 
or are simply unaware, as highlighted by Stokes et al. [18]. 
Thus, the assumption here is that, for those patients when 
NDPP is re-offered to them, a proportion of them will take 
up the programme in the absence of any further measures 
to induce uptake. The model structure was informed by 
a review of the published literature on intervention trials 
Figure 1. State transition diagram.
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and previous model-based economic evaluations focused on 
T2DM prevention programmes, comprising four health 
states: (1) normoglycaemia (healthy FPG or HbA1c), (2) inter-
mediate hyperglycemia (prediabetes), (3) T2DM, and (4) 
death (see Figure 1).
A lifetime time horizon was adopted in this analysis; how-
ever, we present results for a 10-year time horizon. The rea-
sons for opting for a shorter time horizon are that Clinical 
Commissioning Groups (CCGs) are likely to be the main deci-
sion-makers in this context and they are more likely to be 
interested in the impact of an investment on shorter-term 
costs and outcomes [32]. Annual cycles were used to reflect 
the natural history of the disease [7]. An NHS and Personal 
Social Services (PSS) cost perspective was adopted, and costs 
and utilities were discounted at an annual discount rate of 
3.5%, as recommended by NICE [33]. The outcomes of the 
analysis are cost, quality-adjusted life years (QALYs), and net- 
monetary benefit (NMB), where NMB is defined for each inter-
vention as [34]
NMB = QALYs gained × willingness to pay (WTP) for 
a QALY – cost of the intervention
A cost-effectiveness threshold of £20,000-£30,000/QALY 
(US$25,913-US$38,869) was assumed in accordance with 
NICE recommendations [33].
Sensitivity analyses (probabilistic and deterministic) were 
conducted to describe the impact of parameter uncertainty 
on the results.
2.1. Model Description
Individuals enter the model with a diagnosis of prediabetes 
and could remain in the same state, transition to healthy 
(normoglycaemia), T2DM or death. Patients who are healthy 
could remain in the same state, transition back to prediabetes 
or death but not directly to T2DM. Patients with T2DM could 
remain in the same state, transition back to prediabetes or 
death but not to the healthy state. Each cycle in the model 
represents 1 year of a simulated individual’s life and, at the 
end of a cycle, individuals could remain in the same state, 
progress to another state, or die. Figure 1 shows the health 
states and possible transitions.
2.2. Model assumptions
The following base case assumptions were made:
● 15% of the population (previous decliners) will take up 
NDPP when re-offered to them in the absence of any 
further measures to induce uptake (elicited expert opi-
nion, explored in sensitivity analysis).
● Benefits from NDPP occur in the 2 years (9–18 months as 
per NICE guidance) in which NDPP is given [8,35].
● NDPP is associated with a 0.0189 increase in QALYs [36].
● For each arm of the analysis, the transition probability 
from prediabetes to T2DM (conditional on survival) is 
assumed to be constant. This estimate is varied in 
a sensitivity analysis.
● There is no harm associated with NDPP.
● Those with prediabetes who take up NDPP are retained 
in the programme until completion.
2.3. Parameterization
As detailed below, estimates for model parameters were 
based on the published literature and websites of government 
departments in the UK (e.g. Office for National Statistics).
2.3.1. Clinical and epidemiological parameters
The annual transitional probabilities (conditional on survival) 
were based on a meta-analysis [37], a systematic review [38] 
and a longitudinal study [39]. In order to derive missing ele-
ments of the transition matrix, UK death tables were com-
bined with estimates from the above studies. All-cause age- 
dependent mortality rates were determined from the Office 
for National Statistics in England [40], with increased risk of 
death calculated for prediabetes and T2DM. Table 1 shows the 
transitional probabilities used in the economic model.
2.3.2. Costs
Costs were measured in UK pound sterling (£) (for the 2018 
cost year) and were informed by four sources [5,8,41,42]. All 
monetary values have also been reported in United States dol-
lars (US$) in parentheses for the same cost year. In line with the 
assumption used in the NICE costing template, we assumed the 
cost of T2DM increases linearly from the time of diagnosis, to 
reflect the increasing cost of T2DM complications over time [43]. 
Calculating the expected costs for the usual care arm involved, 
for each cycle, adding the costs of each state weighted by the 
proportion in the state, and then adding across cycles [44]. The 
same principle was followed to calculate the expected costs for 
the NDPP arm. However, in this case, the cost of NDPP was 
added to the usual care costs to determine the cost per cycle 
for each state (for the duration of the NDPP). Table 2 shows the 
costs used in the economic analysis.
2.3.3. Utilities
Health-related quality of life outcomes were modeled in 
QALYs, taking into account both quality of life and survival. 
Utility estimates were informed by a cross-sectional study 
conducted in Sweden that used SF-36 questionnaires and 
converted responses using the SF-6D index to utilities [46]. 
Given that there is as yet no publicly available direct data 
collected on the effectiveness of the NDPP, the analysis 
assumes that effectiveness will be similar to that obtained in 
pragmatic trials of lifestyle interventions aimed at preventing 
T2DM, while also undertaking sensitivity analysis around this 
assumption. The relative effectiveness of the NDPP was mod-
eled by applying relative risk to the rate of progression to 
Table 1. Transition matrix between health states (transition probability to death 
is excluded from this table because it is age dependent and, as such, not static).
NDPP (Usual care)
From\to Prediabetes Healthy T2DM
Prediabetes 0.88318 (0.87481) 0.09055 (0.08969) 0.02627 (0.0355)
Healthy 0.0686 (0.0686) 0.9314 (0.9341) 0 (0)
T2DM 0.005 (0.005) 0 (0) 0.995
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diabetes. Incremental utility associated with NDPP was drawn 
from the USDPP [36]. Calculating the expected utility for the 
usual care arm involved, for each cycle, adding the utilities of 
each state weighted by the proportion in the state, and then 
adding across cycles. Following the same principle, the 
expected utility for the NDPP arm was calculated. However, 
in this case, incremental utilities associated with NDPP were 
added to the usual care utilities for each state (for the duration 
of the NDPP). Table 2 also shows the utilities used in the 
economic analysis.
2.4. Analyses
Given this is an early economic evaluation, it is useful to draw 
insights on the maximum price for an intervention that 
improves uptake to NDPP. Headroom analysis (i.e. the max-
imum allowable intervention price at which it is still consid-
ered cost-effective) was conducted using NMB [47], at various 
uptake levels using a WTP threshold of £20,000/QALY (US$ 
25,913). For each uptake level considered, outputs from both 
the deterministic analysis and probabilistic sensitivity analysis 
(PSA) were used.
Probabilistic sensitivity analysis was undertaken to charac-
terize the decision uncertainty and test the robustness of 
parameter estimates [48]. Where possible, distributions were 
attached to probabilities, utilities and costs in the model. Beta 
distributions were attached to probabilities and utilities, and 
gamma distributions were attached to costs. The model was 
run for 10,000 iterations, each time randomly selecting a value 
for each parameter from their respective distributions. Mean 
costs and QALYs were calculated by averaging across all 
10,000 iterations. Table 2 also shows the distribution assigned 
to each model parameter.
Value of information (VOI) analysis was conducted to pro-
vide insights into the potential value of reducing uncertainty 
by conducting further research. For each uptake level exam-
ined, VOI analysis was conducted for the maximum price 
estimated at that uptake level. The overall value of reducing 
uncertainty for each uptake level is presented using the 
expected value of perfect information (EVPI). In VOI analysis, 
insight into the parameters that cause the most decision 
uncertainty and the potential value of reducing the uncer-
tainty by collecting more data were examined using expected 
value of partial perfect information (EVPPI). In this study, EVPPI 
was estimated for each uptake level using SAVI (Sheffield 
Accelerated Value of Information) [49]. The number of patients 
considered to be affected by the decision annually is 1,099,104 
[50,51].
3. RESULTS
3.1. Headroom Analysis Using Net Monetary Benefit
As shown in Figure 2, at a WTP threshold of £20,000/QALY (US 
$ 25,913) and for 5 percentage points increase in uptake of 
NDPP, the intervention can be priced up to £41.86 (US$ 54.23) 
per person and still allow the NDPP to be delivered in 
a manner that remains cost-effective. The figures for the 
other uptake levels are presented in the Appendix. The max-
imum price at which the intervention can be priced and still 
allow the NDPP to be delivered in a cost-effective manner are 
summarized in Table 3 for all the uptake levels considered. The 
results show that, as uptake levels increase, the headroom 
increases. Adopting a lifetime time horizon increases the max-
imum allowable intervention price at all uptake levels consid-
ered. Taking into account the uncertainty around each 
parameter in the model in a probabilistic sensitivity analysis 
produced slightly lower maximum price estimates.
3.2. Value of Information Analysis
As shown in Figure 3, at the WTP threshold adopted and for 
5 percentage points increase in uptake of NDPP, the overall 
EVPI for the specified decision relevance time horizon of 
10 years is £361,818,839 (US$ 468,786,625). Driving this high 
value is the high number of patients affected by the decision 
annually. The figures for the other uptake levels are presented 
in the Appendix. Table 4 gives a summary of per person EVPI 
and the overall EVPI for each of the uptake levels considered 
in this analysis. The results show that, as uptake levels 
Table 2. Model parameters and parameters of gamma and beta distributions.
Cost Parameters Value (£)
Parameters of gamma distribution Data source
a b
Usual care cost per cycle – Prediabetes (PreD.c) 869 69.07 12.58 [41,42]
Usual care cost per cycle – Healthy (Hthy.c) 773 56.73 13.63 [41,42]
Usual care cost per cycle – T2DM (T2DM.c) 1179 19.07 61.83 [5,8]





Utility parameters Value (QALY) Parameters of beta distributions
a b
Utility – Prediabetes (PreD.u) 0.759 10.72 3.4 [46]
Utility – Healthy (Hthy.u) 0.768 12.92 3.9 [46]
Utility – T2DM (T2DM.u) 0.738 9.17 3.26 [46]
Incremental utility associated with NDPP (Inc.u) 0.0189 350.44 18,191.35 [35]
Probability parameters Value Parameters of beta distribution
a b
Percentage of NDPP uptake (when re-offered) (P_NDPP_re) 0.15 2 11.33 Clinical expert opinion
Transitional probability (prediabetes to T2DM) (TP_T2DM) 0.0355 2 54.34 [37]
Relative risk of developing T2DM during NDDP (RR_T2DM) 0.74 5.69 2 [45]
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increase, the overall expected value of removing decision 
uncertainty increases.
Table 5 shows the summary of the single-parameter EVPPI 
for different uptake levels at the WTP threshold adopted 
with a time horizon of 10 years. As shown in the table, 
regardless of the uptake level considered, all the model 
parameters are noted to contribute to the overall decision 
uncertainty. For 5 percentage and 10 percentage points 
increase in uptake, it is noted that the parameter causing 
most of the decision uncertainty in both scenarios is the 
percentage of NDPP uptake (when reoffered), whereas 
incremental utility associated with NDPP and usual care 
cost per cycle for the healthy state are the parameters caus-
ing the least uncertainty respectively. However, for the rest 
of the uptake levels considered, it is noted that utility asso-
ciated with T2DM state is the parameter causing most of the 
decision uncertainty and, cost per cycle for the healthy state 
is the parameter causing the least uncertainty. Figure 4 
shows the single parameter EVPPI for 5 percentage points 
increase in uptake. The figures for the other uptake levels 
are presented in the Appendix. Adopting a lifetime time 
horizon increases the EVPI and EVPPI at all uptake levels 
considered.
4. DISCUSSION
Using an early model-based economic evaluation, this study 
sought to examine whether investment in interventions to 
improve uptake of the NDPP has the potential to be cost- 
effective. A particular focus of this evaluation was to gain insights 
into the maximum allowable intervention price at each uptake 
level considered required for the NDPP to still be delivered in 
a manner that remains cost-effective and the potential value of 
further research to resolve uncertainty at each uptake level.
Figure 2. Headroom for 5% points increase in uptake of NDPP.





intervention price in £ (US$) 
deterministic model
Maximum allowable 
intervention price from 
PSA in £ (US$)
5% 41.86 (54.23) 41.71 (54.04)
10% 83.72 (108.47) 83.52 (108.21)
15% 125.58 (162.70) 125.32 (162.37)
20% 167.44 (216.95) 167.13 (216.54)
25% 209.30 (271.18) 208.93 (270.70)
30% 251.15 (325.40) 250.74 (324.87)
35% 293.01 (379.63) 292.54 (379.03)
40% 334.87 (433.87) 334.35 (433.19)
45% 376.73 (488.10) 376.15 (487.36)
50% 418.59 (542.34) 417.96 (541.52)
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In an era of ever-increasing demand to demonstrate value 
for money, innovators can no longer assume that interven-
tions developed will be adopted and funded. Thus, research 
and development of new interventions should always be dri-
ven by considerations of value to payers of health care and 
early economic evaluation has much conceptual attractiveness 
in this regard [51]. Early economic evaluation is a useful tool 
that can be used by innovators to demonstrate the value of 
a new intervention to payers and to understand the expected 
commercial viability, the risks, and the potential return on 
investment in the intervention.
The headroom analysis shows the maximum price at which 
the intervention can be priced and still be considered cost- 
effective for the different uptake levels considered. For exam-
ple, it is noted that for 5 percentage points increase in NDPP 
uptake, the intervention can be priced up to £41.86 (US$ 
54.23) per person and still allow the NDPP to be delivered in 
a manner that remains cost-effective. Thus, if this price is not 
consistent with an acceptable return on investment (at this 
uptake level), then resources should not be committed to the 
further development of the intervention. The same principle 
applies to the other uptake levels considered in this analysis. 
Furthermore, it is noted from the headroom analysis that as 
uptake levels increase, the maximum price at which the inter-
vention can be priced also increases. For example, for 10 per-
centage points increase in uptake of NDPP, the intervention 
can be priced up to £83.72 (US$ 108.47) per person and, for 
50 percentage points increase in uptake of NDPP, the inter-
vention can be priced up to £418.59 (US$ 542.34) per person. 
Thus, it can be concluded that an innovator will gain most 
from the intervention at higher uptake levels. However, it is 
worth stating that in the case of this analysis, although poten-
tially there is a greater chance of a return on investment at 
a higher price, it also increases the likelihood of rejection on 
budget impact grounds. It is also noted from the headroom 
analysis that although both approaches used in estimating the 
headroom produced similar results, the results obtained from 
Figure 3. VOI analysis results for a 5 percentage points increase in uptake of NDPP.
Table 4. Summary of per person EVPI and overall EVPI for different uptake 
levels.
Percentage points increase in 
uptake
Per person EVPI £ 
(US$) EVPI/10 years £ (US$)
5% 38.24 (49.55) 361,818,839 
(468,786,625)
10% 47.01 (60.91) 444,717,279 
(576,193,083)
15% 58.14 (75.33) 550,083,705 
(712,709,941)
20% 70.62 (91.50) 668,156,843 
(865,690,113)
25% 83.90 (108.71) 793,710,213 
(1,028,361,964)
30% 97.66 (126.53) 923,936,527 
(1,197,088,264)
35% 111.78 (144.83) 1,057,482,378 
(1,370,115,487)
40% 126.12 (163.40) 1,193,203,326 
(1,545,960,851)
45% 140.63 (182.20) 1,330,427,513 
(1,723,753,868)
50% 155.24 (201.13) 1,468,712,316 
(1,902,921,063)
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using the PSA outputs were slightly lower. This is quite intui-
tive considering the fact that the deterministic model takes no 
account of uncertainty in model parameters.
It is worth mentioning that it was not our intention with this 
analysis to evaluate any one intervention aimed at increasing the 
NDPP participation rate in previous programme decliners. 
However, given the issues with participation rates and the subse-
quent impact on the cost-effectiveness of such programmes, the 
benefits of conducting such an analysis is that it provides an idea 
of the price an intervention would have to fall under to have an 
acceptable cost-effectiveness profile. We acknowledge that there 
is an additional step needed to translate our acceptable price 
estimates to the cost of a new intervention depending on the 
form of the intervention, how it is going to be delivered and for 
how long.
It is shown in the VOI analysis that for the specified decision 
relevance time horizon of 10 years adopted in this study and 
for 5 percentage points increase in uptake of NDPP, the overall 
expected value of removing decision uncertainty when the 
intervention is £41.86 (US$ 54.23) per person is £361,818,839 
(US$ 468,786,625). This implies that any further research exer-
cise to resolve uncertainty costing more than this amount will 
not represent a cost-effective use of resources. Furthermore, 
the VOI analysis shows that, as uptake levels increase, the 
overall expected value of removing decision uncertainty 
increases. For example, for 10 percentage points increase in 
uptake, the expected value of removing decision uncertainty 
is £444,717,279 (US$ 576,193,083) and, for 50 percentage 
points increase in uptake, the expected value of removing 
decision uncertainty is £1,468,712,316 (US$ 1,902,921,063). 
From these values, it can be concluded that there is potential 
value in resolving uncertainty (with increasing value at higher 
uptake levels) as any research on further data collection are 
not likely to cost more than the estimated values.
The single-parameter EVPPI results show that all model 
parameters contribute to the decision uncertainty. It is noted 
that for the majority of uptake levels considered, the 
parameter causing most of the uncertainty is the utility asso-
ciated with T2DM state. The EVPPI results demonstrate where 
future research should be focused. It is important to recognize 
that these values for EVPI and EVPPI are upper bounds, and 
form limit values to guide only whether further research may 
be cost-effective, rather than guarantee that it necessarily is. 
Adopting a lifetime time horizon increases the maximum 
allowable intervention price as well as EVPI and EVPPI at all 
uptake levels considered.
Early economic evaluation has potentially profound advan-
tages for innovators and its implementation will promote 
efficiency from the outset of the development of a new inter-
vention [29]. However, conducting economic evaluations so 
early in the evidence pipeline means that there are often 
limitations and/or uncertainties associated with some of the 
data used to parameterize the model. For example, where 
primary data is lacking, elicited expert opinion may be relied 
upon for model parameterization. It is important therefore to 
explore the impact of these parameters on the cost- 
effectiveness argument via sensitivity analyses. Here, a key 
driver of decision uncertainty was the proportion of pre- 
diabetics who would take up NDPP if it was re-offered to 
them, an estimate based on expert opinion.
4.1. Strengths and limitations of the study
To the best of our knowledge, this is the first study that has 
focused on evaluating the potential cost-effectiveness of inter-
ventions to increase uptake to the NDPP. Another strength of 
this analysis is the use of multiple sources of evidence to 
parameterize a full model-based economic evaluation includ-
ing systematic reviews, meta-analyses, and other economic 
models. Furthermore, it highlights the usefulness of using 
the early economic evaluation to explore the headroom for 
a new intervention and potential price-points.
Owing to the timing of this evaluation in the evidence 
pipeline, some of the data used to parameterize the model 
Figure 4. Single parameter EVPPI for a 5 percentage points increase in uptake of NDPP.
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are associated with considerable uncertainty. This is 
accounted for within the analysis via the probabilistic sensi-
tivity analysis.
5. Conclusion
This analysis explored whether there is headroom for invest-
ment in interventions that improve uptake to the NDPP. The 
results demonstrate that there is room for investment, and the 
maximum price increases as the potential effectiveness of the 
intervention increases (i.e. improvement in NDPP uptake 
levels). The estimated maximum price that the intervention 
can be priced and still allow the NDPP to be delivered in 
a manner that remains cost-effective for 5 percentage and 
50 percentage points increase in uptake of NDPP are £41.86 
(US$ 54.23) and £418.59 (US$ 542.34) per person, respectively. 
The analysis shows further that, as uptake levels increase, the 
overall expected value of removing decision uncertainty 
increases.
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